 Enrique Alvarez
Concepts (291)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 39 | 2025 | 455 | 7.990 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 11 | 2024 | 76 | 2.460 |
Why?
| | Immunologic Factors | 7 | 2020 | 236 | 2.420 |
Why?
| | Fingolimod Hydrochloride | 6 | 2020 | 40 | 2.260 |
Why?
| | Natalizumab | 5 | 2023 | 40 | 2.200 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 6 | 2023 | 28 | 2.110 |
Why?
| | Rituximab | 6 | 2023 | 176 | 1.730 |
Why?
| | Immunosuppressive Agents | 9 | 2024 | 890 | 1.300 |
Why?
| | Agammaglobulinemia | 2 | 2023 | 34 | 0.990 |
Why?
| | Dimethyl Fumarate | 3 | 2020 | 12 | 0.990 |
Why?
| | Neuromyelitis Optica | 4 | 2020 | 132 | 0.710 |
Why?
| | Serum Sickness | 1 | 2019 | 6 | 0.640 |
Why?
| | Medical Marijuana | 1 | 2018 | 117 | 0.520 |
Why?
| | Pregnancy Complications | 2 | 2018 | 527 | 0.510 |
Why?
| | Lymphocyte Depletion | 3 | 2021 | 135 | 0.500 |
Why?
| | Axons | 2 | 2014 | 198 | 0.480 |
Why?
| | Marijuana Smoking | 1 | 2018 | 252 | 0.470 |
Why?
| | Oligoclonal Bands | 1 | 2014 | 20 | 0.460 |
Why?
| | Neurofilament Proteins | 1 | 2014 | 52 | 0.450 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2023 | 804 | 0.430 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1050 | 0.420 |
Why?
| | Anemia | 1 | 2015 | 170 | 0.410 |
Why?
| | Biomarkers | 3 | 2023 | 4149 | 0.410 |
Why?
| | Chemokine CXCL13 | 1 | 2013 | 8 | 0.410 |
Why?
| | Humans | 55 | 2024 | 137585 | 0.390 |
Why?
| | Recurrence | 6 | 2024 | 1060 | 0.390 |
Why?
| | Adult | 27 | 2024 | 37929 | 0.380 |
Why?
| | Middle Aged | 27 | 2024 | 33479 | 0.360 |
Why?
| | Antibodies, Monoclonal | 4 | 2022 | 1430 | 0.350 |
Why?
| | Female | 34 | 2025 | 73304 | 0.320 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1996 | 0.310 |
Why?
| | Brain | 7 | 2021 | 2668 | 0.300 |
Why?
| | Magnetic Resonance Imaging | 8 | 2022 | 3566 | 0.290 |
Why?
| | Glatiramer Acetate | 2 | 2019 | 18 | 0.280 |
Why?
| | Walking | 4 | 2023 | 529 | 0.280 |
Why?
| | Demyelinating Diseases | 3 | 2025 | 85 | 0.280 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 449 | 0.280 |
Why?
| | Male | 30 | 2025 | 67762 | 0.270 |
Why?
| | Antigens, CD20 | 2 | 2023 | 29 | 0.250 |
Why?
| | B-Lymphocytes | 3 | 2023 | 847 | 0.240 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 73 | 0.230 |
Why?
| | Remyelination | 1 | 2025 | 15 | 0.230 |
Why?
| | Multigene Family | 1 | 2005 | 198 | 0.230 |
Why?
| | Retrospective Studies | 9 | 2024 | 15657 | 0.210 |
Why?
| | Atrophy | 2 | 2021 | 184 | 0.210 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 68 | 0.210 |
Why?
| | Neuroprotection | 1 | 2023 | 42 | 0.210 |
Why?
| | Diphosphonates | 1 | 2003 | 66 | 0.200 |
Why?
| | Alemtuzumab | 1 | 2023 | 15 | 0.200 |
Why?
| | Bone Resorption | 1 | 2003 | 86 | 0.200 |
Why?
| | Myelin Sheath | 1 | 2025 | 167 | 0.200 |
Why?
| | Cellular Senescence | 1 | 2025 | 189 | 0.200 |
Why?
| | Fatigue | 2 | 2024 | 329 | 0.200 |
Why?
| | Microglia | 1 | 2025 | 251 | 0.190 |
Why?
| | Treatment Outcome | 8 | 2024 | 10811 | 0.190 |
Why?
| | Gadolinium | 2 | 2022 | 82 | 0.190 |
Why?
| | Interoception | 1 | 2021 | 2 | 0.190 |
Why?
| | Drug Costs | 1 | 2023 | 106 | 0.180 |
Why?
| | Neuroblastoma | 1 | 2023 | 160 | 0.180 |
Why?
| | Diagnostic Self Evaluation | 1 | 2021 | 23 | 0.180 |
Why?
| | Inflammation | 1 | 2013 | 2837 | 0.180 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 596 | 0.180 |
Why?
| | Stair Climbing | 1 | 2021 | 2 | 0.180 |
Why?
| | Muscle, Skeletal | 5 | 2024 | 1724 | 0.180 |
Why?
| | Quality of Life | 4 | 2023 | 2892 | 0.180 |
Why?
| | Resistance Training | 1 | 2024 | 164 | 0.170 |
Why?
| | Hippocampus | 3 | 2002 | 895 | 0.170 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 860 | 0.170 |
Why?
| | Lymphopenia | 1 | 2020 | 62 | 0.170 |
Why?
| | Personality | 1 | 2021 | 132 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 789 | 0.160 |
Why?
| | Torso | 1 | 2020 | 33 | 0.160 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2002 | 100 | 0.160 |
Why?
| | Neutropenia | 1 | 2020 | 146 | 0.160 |
Why?
| | Cancer Vaccines | 1 | 2021 | 172 | 0.160 |
Why?
| | Muscle Strength | 2 | 2024 | 317 | 0.160 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2019 | 23 | 0.160 |
Why?
| | Disease Management | 1 | 2023 | 628 | 0.150 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 480 | 0.150 |
Why?
| | Pelvis | 1 | 2020 | 102 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 210 | 0.150 |
Why?
| | Receptors, Glutamate | 1 | 1999 | 25 | 0.150 |
Why?
| | Sodium Glutamate | 1 | 1999 | 12 | 0.150 |
Why?
| | Young Adult | 6 | 2021 | 13209 | 0.150 |
Why?
| | Nerve Net | 1 | 2021 | 256 | 0.150 |
Why?
| | Double-Blind Method | 5 | 2022 | 1993 | 0.150 |
Why?
| | Avoidance Learning | 1 | 1999 | 76 | 0.140 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 89 | 0.140 |
Why?
| | Muscle Spasticity | 1 | 2018 | 58 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 250 | 0.140 |
Why?
| | Dendritic Cells | 1 | 2021 | 483 | 0.140 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 327 | 0.140 |
Why?
| | Reaction Time | 1 | 1999 | 412 | 0.130 |
Why?
| | Electric Stimulation Therapy | 1 | 2018 | 81 | 0.130 |
Why?
| | Interferon beta-1a | 1 | 2016 | 12 | 0.130 |
Why?
| | Postural Balance | 1 | 2019 | 215 | 0.130 |
Why?
| | Gait | 1 | 2020 | 296 | 0.130 |
Why?
| | Psychomotor Performance | 1 | 2019 | 309 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5131 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 417 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2023 | 852 | 0.130 |
Why?
| | Patient Care Planning | 1 | 2017 | 157 | 0.130 |
Why?
| | Disease Progression | 5 | 2022 | 2757 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2017 | 83 | 0.130 |
Why?
| | Transcription Factor RelA | 1 | 2016 | 87 | 0.130 |
Why?
| | Lymphocyte Activation | 2 | 2019 | 1142 | 0.130 |
Why?
| | CD40 Antigens | 1 | 2016 | 89 | 0.120 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 117 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 786 | 0.120 |
Why?
| | Movement | 3 | 2023 | 278 | 0.120 |
Why?
| | Contrast Media | 1 | 2018 | 467 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 910 | 0.110 |
Why?
| | Survival Analysis | 1 | 2018 | 1325 | 0.110 |
Why?
| | Pyridines | 1 | 2018 | 506 | 0.110 |
Why?
| | Postpartum Period | 1 | 2017 | 340 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 320 | 0.110 |
Why?
| | Monocytes | 1 | 2017 | 563 | 0.110 |
Why?
| | Melanoma | 1 | 2021 | 760 | 0.110 |
Why?
| | Neurons | 3 | 2011 | 1590 | 0.110 |
Why?
| | Disability Evaluation | 4 | 2018 | 290 | 0.110 |
Why?
| | Patient Participation | 1 | 2017 | 420 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2021 | 855 | 0.100 |
Why?
| | Pain | 1 | 2018 | 756 | 0.100 |
Why?
| | Pain, Intractable | 1 | 2012 | 10 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2017 | 293 | 0.100 |
Why?
| | Rats | 5 | 2005 | 5647 | 0.090 |
Why?
| | Dopamine | 2 | 2005 | 303 | 0.090 |
Why?
| | Time Factors | 2 | 2021 | 6828 | 0.090 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 37 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 86 | 0.090 |
Why?
| | Health Personnel | 1 | 2017 | 710 | 0.090 |
Why?
| | Antigen-Presenting Cells | 1 | 2011 | 156 | 0.090 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 413 | 0.090 |
Why?
| | Aged | 6 | 2024 | 23961 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2017 | 1164 | 0.090 |
Why?
| | Decision Making | 1 | 2017 | 900 | 0.080 |
Why?
| | Hypoxia | 1 | 2017 | 1112 | 0.080 |
Why?
| | Leukocytes | 1 | 2011 | 311 | 0.080 |
Why?
| | Neoplasms | 1 | 2024 | 2671 | 0.080 |
Why?
| | Animals | 8 | 2025 | 36940 | 0.080 |
Why?
| | Adolescent | 4 | 2021 | 21513 | 0.080 |
Why?
| | Immunoglobulin G | 2 | 2023 | 893 | 0.080 |
Why?
| | Lymphocytes | 1 | 2011 | 397 | 0.080 |
Why?
| | Pregnancy | 2 | 2018 | 6763 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2013 | 3556 | 0.070 |
Why?
| | Spinal Cord | 2 | 2012 | 370 | 0.070 |
Why?
| | Biomechanical Phenomena | 2 | 2021 | 810 | 0.070 |
Why?
| | MicroRNAs | 1 | 2013 | 692 | 0.070 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 265 | 0.060 |
Why?
| | Microinjections | 3 | 2002 | 86 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 52 | 0.060 |
Why?
| | Immunologic Memory | 2 | 2019 | 353 | 0.060 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2005 | 155 | 0.060 |
Why?
| | Chemokine CCL11 | 1 | 2025 | 26 | 0.060 |
Why?
| | Pilot Projects | 2 | 2021 | 1710 | 0.060 |
Why?
| | Organ Specificity | 1 | 2005 | 305 | 0.060 |
Why?
| | Cytoplasm | 1 | 2005 | 274 | 0.060 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2005 | 156 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 10388 | 0.050 |
Why?
| | Species Specificity | 1 | 2005 | 585 | 0.050 |
Why?
| | Electric Stimulation | 2 | 2021 | 264 | 0.050 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2003 | 24 | 0.050 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2004 | 72 | 0.050 |
Why?
| | Osteolysis | 1 | 2003 | 18 | 0.050 |
Why?
| | Models, Biological | 1 | 2011 | 1783 | 0.050 |
Why?
| | Nerve Growth Factors | 1 | 2004 | 79 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 767 | 0.050 |
Why?
| | Aging | 2 | 2025 | 1864 | 0.050 |
Why?
| | Oligodendroglia | 1 | 2025 | 179 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5472 | 0.050 |
Why?
| | Mice | 3 | 2025 | 17787 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2085 | 0.050 |
Why?
| | Pluripotent Stem Cells | 1 | 2004 | 80 | 0.050 |
Why?
| | Crotonates | 1 | 2022 | 5 | 0.050 |
Why?
| | Toluidines | 1 | 2022 | 7 | 0.050 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2022 | 4 | 0.050 |
Why?
| | Hydroxybutyrates | 1 | 2022 | 14 | 0.050 |
Why?
| | Kynurenic Acid | 1 | 2002 | 20 | 0.050 |
Why?
| | Arm | 1 | 2023 | 104 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2022 | 28 | 0.050 |
Why?
| | Histamine | 1 | 1982 | 67 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2005 | 620 | 0.050 |
Why?
| | Maze Learning | 1 | 2002 | 103 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 1167 | 0.050 |
Why?
| | Behavior, Animal | 2 | 2002 | 501 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 131 | 0.050 |
Why?
| | Cell Division | 1 | 2003 | 794 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2024 | 474 | 0.050 |
Why?
| | Base Sequence | 1 | 2005 | 2181 | 0.050 |
Why?
| | Nitriles | 1 | 2022 | 172 | 0.050 |
Why?
| | Heart | 1 | 2005 | 655 | 0.050 |
Why?
| | MART-1 Antigen | 1 | 2021 | 12 | 0.050 |
Why?
| | Gray Matter | 1 | 2022 | 80 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 157 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 310 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 658 | 0.040 |
Why?
| | Research Report | 1 | 2021 | 83 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2900 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1120 | 0.040 |
Why?
| | Neuroimaging | 1 | 2022 | 259 | 0.040 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 219 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 61 | 0.040 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 198 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 327 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2024 | 956 | 0.040 |
Why?
| | Drug Substitution | 1 | 2019 | 54 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 350 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 625 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2019 | 148 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 35 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2023 | 553 | 0.040 |
Why?
| | Motor Skills | 1 | 2019 | 97 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
| | Hand | 1 | 2019 | 156 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1774 | 0.040 |
Why?
| | Proteomics | 1 | 2025 | 1111 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 79 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1236 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 148 | 0.040 |
Why?
| | Leg | 1 | 2019 | 236 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 621 | 0.030 |
Why?
| | Headache | 1 | 2018 | 147 | 0.030 |
Why?
| | Organ Size | 1 | 2018 | 477 | 0.030 |
Why?
| | Knee Joint | 1 | 2021 | 409 | 0.030 |
Why?
| | Tumor Escape | 1 | 2017 | 42 | 0.030 |
Why?
| | Macrophages | 1 | 2025 | 1547 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1389 | 0.030 |
Why?
| | Memory | 1 | 1999 | 248 | 0.030 |
Why?
| | Internet | 1 | 2021 | 655 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2017 | 224 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1943 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1477 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 209 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 385 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2004 | 1991 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 499 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 171 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2003 | 3412 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5742 | 0.030 |
Why?
| | Patient Preference | 1 | 2017 | 191 | 0.030 |
Why?
| | Risk | 1 | 2017 | 912 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 522 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 322 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5757 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2553 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1066 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2804 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 4030 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1289 | 0.020 |
Why?
| | Genetic Markers | 1 | 2013 | 344 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2129 | 0.020 |
Why?
| | Patient-Centered Care | 1 | 2017 | 530 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1759 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 431 | 0.020 |
Why?
| | Prospective Studies | 1 | 2024 | 7604 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2023 | 6079 | 0.020 |
Why?
| | Down-Regulation | 1 | 2013 | 657 | 0.020 |
Why?
| | Pain Measurement | 1 | 2012 | 521 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 1069 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 352 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1397 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2031 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7635 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2828 | 0.010 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2004 | 17 | 0.010 |
Why?
| | Cell Shape | 1 | 2004 | 57 | 0.010 |
Why?
| | Mesencephalon | 1 | 2004 | 66 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 110 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 112 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 239 | 0.010 |
Why?
| | Grooming | 1 | 1982 | 8 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2004 | 176 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 27 | 0.010 |
Why?
| | Corpus Striatum | 1 | 2004 | 167 | 0.010 |
Why?
| | Rats, Inbred Strains | 1 | 1982 | 362 | 0.010 |
Why?
| | Oligonucleotides, Antisense | 1 | 2002 | 112 | 0.010 |
Why?
| | Astrocytes | 1 | 2004 | 210 | 0.010 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2002 | 124 | 0.010 |
Why?
| | Catheterization | 1 | 2002 | 179 | 0.010 |
Why?
| | Locomotion | 1 | 1982 | 106 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 167 | 0.010 |
Why?
| | United States | 1 | 2018 | 14841 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1092 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 1226 | 0.010 |
Why?
| | Action Potentials | 1 | 2002 | 493 | 0.010 |
Why?
| | Parkinson Disease | 1 | 2004 | 493 | 0.010 |
Why?
| | Gene Expression | 1 | 2002 | 1502 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2475 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4193 | 0.010 |
Why?
| | Phenotype | 1 | 2004 | 3196 | 0.010 |
Why?
|
|
Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|